TP, RM, SN, OE, AC, and OH wrote the report. All other authors declare no competing interests.This study was funded by the UK Medical Research Council (MC-A656-5QD30), Maudsley Charity (666), Brain and Behavior Research Foundation, and Wellcome Trust ( 094849/Z/10/Z ) grants to ODH and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, and NIHR Oxford Health Biomedical Research Centre at Oxford Health NHS Foundation Trust. Side Effects Metabolic: The second-generation antipsychotics, however, are more likely than the first-generation antipsychotics to induce metabolic syndrome by inducing resistance at insulin receptors by an unclear mechanism. Marked differences exist between antipsychotics in terms of metabolic side-effects, with olanzapine and clozapine exhibiting the worst profiles and aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone the most benign profiles.

Despite attempts made to contact authors, we were unable to obtain metabolic data for several trials, especially if the study was done more than 15 years ago.
TP, OE, and RM did the statistical analyses. 2005 Jun;27(5):289-304. doi: 10.1358/mf.2005.27.5.908643.Prog Brain Res. However, concerns about EPS have been replaced by concerns about other side effects, such as weight gain, glucose dysregulation and dyslipidemia. COVID-19 is an emerging, rapidly evolving situation.
This results in glucose intolerance and shunting of lipids toward central adipose stores. TP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.ODH reports investigator-initiated research funding from AstraZeneca, Autifony, Heptares, Lundbeck, Sunovian, and Roche, and speaker meetings organised by BMS, Eli Lilly, Jansenn, Lundbeck, Lyden-Delta, Sunovion, and Rand. Further work is required to define the metabolic profiles of older drugs, which will better inform prescribing practice. 2010 Jan;125(1):169-79. doi: 10.1016/j.pharmthera.2009.10.010. Emerging evidence suggests that antipsychotics have different liabilities to induce obesity, diabetes and dyslipidemia. A literature review.Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011).Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology.Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.GetReal in network meta-analysis: a review of the methodology.Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study.Sex differences in the metabolic syndrome: implications for cardiovascular health in women.Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada.Network meta-analysis, electrical networks and graph theory.netmeta: Network meta-analysis using frequentist methods.Scientists rise up against statistical significance.The dark side of the force: multiplicity issues in network meta-analysis and how to address them.Ranking treatments in frequentist network meta-analysis works without resampling methods.2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.Evaluating the quality of evidence from a network meta-analysis.Assessing confidence in the results of network meta-analysis (Cinema).Conducting Meta-Analyses in R with the metafor Package.An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown.Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia.Preclinical models of antipsychotic drug-induced metabolic side effects.Weight, weight change, and coronary heart disease in women. Future network meta-analyses should examine antipsychotic-induced metabolic dysregulation in patients receiving long-term maintenance therapy. Please enable it to take advantage of the complete set of features! Name must be less than 100 characters Our meta-regression analyses were based on study-level data and require replication with individual patient data. However, clinical decisions to use preferentially antipsychotics with fewer metabolic side-effects should consider that clinical improvement is associated with development of these side-effects.